The country has reached deals with three major drug firms to
buy enough vaccine doses for its population of 126 million.
But it has not yet announced a detailed roll-out plan for
the jabs, less than six months before the pandemic-postponed Olympics begin.
The Pfizer/BioNTech vaccine is likely to become the first
jab approved for use in Japan in the coming days, following domestic clinical
trials required by the country's health authorities.
"When we have confirmed the vaccine's efficacy and
safety, we will start vaccination by the middle of next week," Prime
Minister Yoshihide Suga said.
Japan is trying to secure enough special syringes that can
extract the full six doses from each vial of Pfizer vaccine.
More commonly used syringes can only draw five doses—meaning
the last one needs to be discarded.
The syringe problem could force the country to forgo enough
Pfizer vaccine doses for up to 12 million people, local media estimated.
"At first, we will use the syringes that can draw six
doses, but as we vaccinate many people, these will become scarce," Health
Minister Norihisa Tamura said on Tuesday.
"We are working hard to secure the syringes. We are
asking medical equipment manufacturers to increase their production," he
told parliament.
Around 10,000 medical workers will be the first people
vaccinated in Japan, with officials hoping to expand the rollout to the elderly
from April.
Toshio Nakagawa, head of the Japan Medical Association, said
that a lack of information about the vaccine campaign is causing confusion
among medical workers.
But he said at a Wednesday press conference that medics are
committed to the vaccination programme, which he called "the most enormous
undertaking, at a scale we have never experienced before".
The jabs "will let us be on the offensive, rather than
just on defence", he added.
0 comments:
Post a Comment